FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 108 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 EMA Recommends Granting a Marketing Authorisation for Acalabrutinib July 30, 2020 Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer June 30, 2025 Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 Load more HOT NEWS Why the voices of people affected by cancer are critical to... A urine test for bladder cancer: What’s the latest? ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed...
